Marker Therapeutics, Inc.

A major leap forward in cell therapy

Pancreatic Cancer Interim Results

The Company

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Reports Full Year 2019 Operating and Financial Results

Marker Therapeutics today provided a corporate update and reported financial results for the full year ended December 31, 2019.

Read more

Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million

Marker Therapeutics today announced that the Company has entered into a Common Stock Purchase Agreement of up to $30 million with Aspire Capital Fund, LLC, a Chicago-based institutional investor and long-term Marker shareholder.

Read more